Medicure Inc (TSXV:MPH)(OTC:MCUJF), a pharmaceutical company, announced yesterday its financial results for the quarter ended 30 June 2019.
The company reported adjusted EBITDA for the quarter ended 30 June 2019 at USD103,000 compared to adjusted EBITDA of USD882,000 for the quarter ended 30 June 2018.
The firm posted net loss for the quarter ended 30 June 2019 at USD957,000 compared to net income of USD1.6m for the quarter ended 30 June 2018.
Net loss for the six months ended 30 June 2019 was USD3.7m or USD0.24 per share. This compares to net income of USD3.0m or USD0.19 per share for the six months ended 30 June 2018.
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation